Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial (Q36761916)
Jump to navigation
Jump to search
scientific article published on 10 September 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial |
scientific article published on 10 September 2015 |
Statements
1 reference
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial (English)
1 reference
Jeremy Sokolove
1 reference
Michael Schiff
1 reference
Roy Fleischmann
1 reference
Michael E Weinblatt
1 reference
Sean E Connolly
1 reference
Alyssa Johnsen
1 reference
Jin Zhu
1 reference
Michael A Maldonado
1 reference
Salil Patel
1 reference
William H Robinson
1 reference
10 September 2015
1 reference
1 reference
709-714
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference